Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

Table 3 Crude incidence rates of malignancies

	n of CA	n	pyrs	IR
Characteristics at baseline
Age (per 10 yrs increase)
Female	52	3,917	9,687	5.4
Male	22	1,081	2,554	8.6
Co-morbid conditions:
COPD
No	63	4,754	11,677	5.4
Yes	11	244	564	19.5
Gastrointestinal disease
No	61	4,579	11,153	5.5
Yes	13	419	1,088	11.9
Renal disease
No	70	4,835	11,884	5.9
Yes	4	163	357	11.2
Characteristics at follow-up
DAS28
<3.2	6	787	2,165	2.8
3.2 to 5.1	34	2,823	7,341	4.6
>5.1	34	1,388	2,735	12.4
Ever exposed to
Conventional DMARDs only	30	1,684 ^#	3,561	8.4
Anti-TNF agents	44	3,651 *	8,558	5.1
Anakinra	5	247 ^$	690	7.2

CA: malignancies, n = number of cases, pyrs = follow-up time in patient years, IR = crude incidence rate per 1,000 pyrs.
^#35 of the patients in the DMARD cohort were exposed to anti-TNF agents before inclusion in the study. According to the ever exposed approach their follow-up time was assigned to the anti-TNF treated group.
* Patients included in this group are patients who were included in the study with the start of an anti-TNF agent (n = 3,201) and patients who changed during follow-up from DMARD or anakinra treatment to anti-TNF treatment
^$223 of the 247 pts were exposed to anakinra and anti-TNF agents, they experienced five malignancies.

ISSN: 1478-6362